← Leaderboards
Saro Armenian
Beckman Research Institute/City Of Hope
$9,494,283
Attributed
$11,545,034
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2013–24$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$11,545,034 · 5
By mechanism
R01$10,802,837 · 3
R21$742,197 · 2
Top collaborators
- Alan C Geller5 shared
Most similar at Beckman Research Institute/City Of Hope
Same institution · by research overlap
- Betty R Ferrell$24,373,896
- Steven Terry Rosen$39,410,931
Others in their field
Top investigators on “Survivors”
- Joseph Sparano · Montefiore Medical Center (Bronx, Ny)$129,558,452
- Laurence H Baker · University Of Michigan At Ann Arbor$81,806,264
- Peter C Adamson · National Childhood Cancer Foundation$64,737,902
- Gregory Armstrong · St. Jude Children'S Research Hospital$61,535,149
- Deborah W Bruner · American College Of Radiology$57,347,005
- Daniel F Hanley · Johns Hopkins University$46,668,549
Research focus
SurvivorsCardiovascular SystemMorbidity - Disease RateHigh RiskClinically RelevantMortalityScreeningCardiotoxicityLong-Term SurvivorsCardiacCancer SurvivorAdultGeneral PopulationConditioningMultidisciplinaryTreatment-Related CancerResearch PriorityCancer SurvivorshipResponseHeart FailurePreventCaringOncologyFuture
Grant awards (19)
Technology-Enabled Activation of Skin Cancer Screening for Hematopoietic Cell Transplantation Survivors and their Primary Care Providers$748,780
R01 · FY2024 · CA · contact PI
Cardiovascular reserve capacity in survivors of hematopoietic cell transplantation$686,465
R01 · FY2024 · HL · contact PI
Technology-Enabled Activation of Skin Cancer Screening for Hematopoietic Cell Transplantation Survivors and their Primary Care Providers$798,150
R01 · FY2023 · CA · contact PI
Cardiovascular reserve capacity in survivors of hematopoietic cell transplantation$700,475
R01 · FY2023 · HL · contact PI
Technology-Enabled Activation of Skin Cancer Screening for Hematopoietic Cell Transplantation Survivors and their Primary Care Providers$806,562
R01 · FY2022 · CA · contact PI
Cardiovascular reserve capacity in survivors of hematopoietic cell transplantation$690,073
R01 · FY2022 · HL · contact PI
Remote monitoring of cardiac function in childhood cancer survivors$174,379
R21 · FY2022 · CA · contact PI
Technology-Enabled Activation of Skin Cancer Screening for Hematopoietic Cell Transplantation Survivors and their Primary Care Providers$838,645
R01 · FY2021 · CA · contact PI
Cardiovascular reserve capacity in survivors of hematopoietic cell transplantation$708,876
R01 · FY2021 · HL · contact PI
Remote monitoring of cardiac function in childhood cancer survivors$222,334
R21 · FY2021 · CA · contact PI
Technology-Enabled Activation of Skin Cancer Screening for Hematopoietic Cell Transplantation Survivors and their Primary Care Providers$909,366
R01 · FY2020 · CA · contact PI
Cardiovascular reserve capacity in survivors of hematopoietic cell transplantation$743,275
R01 · FY2020 · HL · contact PI
Reducing risk of Anthracycline-related heart failure after childhood cancer$562,287
R01 · FY2019 · CA · contact PI
Reducing risk of Anthracycline-related heart failure after childhood cancer$604,525
R01 · FY2018 · CA · contact PI
Reducing risk of Anthracycline-related heart failure after childhood cancer$610,389
R01 · FY2017 · CA · contact PI
Reducing risk of Anthracycline-related heart failure after childhood cancer$669,859
R01 · FY2016 · CA · contact PI
Reducing risk of Anthracycline-related heart failure after childhood cancer$725,110
R01 · FY2015 · CA · contact PI
Anthraycline-related cardiotoxicity in long-term survivors of lymphoma$155,521
R21 · FY2014 · CA · contact PI
Anthraycline-related cardiotoxicity in long-term survivors of lymphoma$189,963
R21 · FY2013 · CA · contact PI